Production (Stage)
Addex Therapeutics Ltd
ADXN
$8.40
$0.192.31%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 7.57M | 5.72M | 4.52M | -12.70M | -11.77M |
| Total Depreciation and Amortization | 216.70K | 192.90K | 134.30K | 13.30K | 13.10K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -12.52M | -12.60M | -13.12M | 2.46M | 2.61M |
| Change in Net Operating Assets | -1.32M | -28.00K | -351.40K | 1.39M | 275.50K |
| Cash from Operations | -6.05M | -6.72M | -8.81M | -8.83M | -8.87M |
| Capital Expenditure | -1.50K | -2.90K | -2.20K | -5.00K | -7.70K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 5.14M | 5.16M | 5.16M | -- | -- |
| Cash from Investing | 5.14M | 5.15M | 5.16M | -5.00K | -7.70K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -73.70K | -141.00K | -210.90K | -234.50K | -281.80K |
| Issuance of Common Stock | 241.00K | 256.10K | 253.90K | 1.41M | 2.35M |
| Repurchase of Common Stock | -25.70K | -29.00K | -49.40K | -43.40K | -50.10K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -36.60K | -37.80K | -133.80K | 3.27M | 3.24M |
| Cash from Financing | 122.10K | 58.20K | -155.10K | 4.90M | 5.82M |
| Foreign Exchange rate Adjustments | 113.40K | -157.70K | -88.50K | -256.10K | -399.20K |
| Miscellaneous Cash Flow Adjustments | -11.60K | -11.60K | -11.60K | -349.80K | -- |
| Net Change in Cash | -686.30K | -1.68M | -3.91M | -4.55M | -3.46M |